Mr. Moradi is a successful entrepreneur, having founded or been a principal in several nanotech and biopharma startups. He is Founder & CEO of Sensulin, which is developing a glucose-responsive insulin for type I/II diabetes. Sensulin's may eliminate the multiple daily insulin injections required by T1D patients.

Mike was a founder and CEO of the #264 fastest growing private company in the 2009 Inc. 500. He co-founded two leading carbon nanotube companies, including Nanopolaris/Unidym, which was acquired by a S. Korean company in 2011. He was also a principal in NanoSource, which was acquired by DuPont (NYSE:DD) in 2002 - widely considered the first liquidity event in nanotech.

Mr. Moradi is a member of The Future Trends Forum, a Madrid-based think tank. In 2003, Mike was awarded a community service commendation by the U.S. Congress. He is the author of The Impact of Nanotechnology in Drug Delivery.

Mike is a former Chairman of Prevent Blindness Oklahoma, a former trustee of the $8.5 billion Oklahoma Public Employees Retirement System (OPERS), Past Chairman of the BioScience Roundtable, a member of the National Science Foundation’s Committee of Visitors, a Director of the OCU Meinders School of Business and Creative Oklahoma. (host of the 2010 Creativity World Forum), etc.

Mr. Moradi earned a B.S. in Biochemistry from the U. of Oklahoma.